Results 151 to 160 of about 106,022 (294)

Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults

open access: yesCriminology, EarlyView.
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of medications widely prescribed for diabetes and obesity, have exhibited emerging effects on substance use, reward processing, and impulse control. This study examines whether current GLP‐1 RA use moderates established behavioral pathways to violent crime from impulsivity and ...
Daniel C. Semenza, Christopher Thomas
wiley   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale   +5 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists as a Potential Mitochondrial Modulation Therapy for Hidradenitis Suppurativa. [PDF]

open access: yesActa Derm Venereol
Hosseini A   +4 more
europepmc   +1 more source

Impact of bariatric surgery on alcohol‐use disorder and alcohol‐related liver disease: A retrospective study

open access: yesAddiction, EarlyView.
Abstract Background and aims Increased risk of alcohol dependence is recognised following bariatric surgery. Modified gastrointestinal anatomy and neurohormonal profiles lead to altered alcohol metabolism, peak blood alcohol concentrations and enhanced reward circuits and cravings.
Thomas J. Williams   +4 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. [PDF]

open access: yesDiabetes Ther
Panou T   +4 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Readability of AI-Generated Patient Information on Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

open access: yesJMIR Bioinform Biotechnol
Williams T   +6 more
europepmc   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy